A multi-centre, randomised, double blind, placebo controlled trial to investigate the effect of bicalutamide (Casodex) 150mg on the pharmacokinetics of midazolam in prostate cancer patients

Trial Profile

A multi-centre, randomised, double blind, placebo controlled trial to investigate the effect of bicalutamide (Casodex) 150mg on the pharmacokinetics of midazolam in prostate cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2008

At a glance

  • Drugs Bicalutamide (Primary) ; Midazolam
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top